Article

Human Immunodeficiency Virus Type 1 Tat Protein Inhibits the SIRT1 Deacetylase and Induces T Cell Hyperactivation

Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94158, USA.
Cell host & microbe (Impact Factor: 12.19). 04/2008; 3(3):158-67. DOI: 10.1016/j.chom.2008.02.002
Source: PubMed

ABSTRACT Symptoms of T cell hyperactivation shape the course and outcome of HIV-1 infection, but the mechanism(s) underlying this chronic immune activation are not well understood. We find that the viral transactivator Tat promotes hyperactivation of T cells by blocking the nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase SIRT1. Tat directly interacts with the deacetylase domain of SIRT1 and blocks the ability of SIRT1 to deacetylate lysine 310 in the p65 subunit of NF-kappaB. Because acetylated p65 is more active as a transcription factor, Tat hyperactivates the expression of NF-kappaB-responsive genes, a function lost in SIRT1-/- cells. These results support a model where the normal function of SIRT1 as a negative regulator of T cell activation is suppressed by Tat during HIV infection. These events likely contribute to the state of immune cell hyperactivation found in HIV-infected individuals.

0 Followers
 · 
134 Views
    • "Studies reveal that SIRT1 exerts effects on the immune system by regulating the activity of T cells. Kwon et al. (2008) reported that blocking SIRT1 induces T cell hyperactivation, suggesting that SIRT1 acts as a negative regulator of T cell activation. Zhang et al. (2009) also found that the loss of SIRT1 functionality resulted in abnormally increased T cell activation and a breakdown of CD4þ T cell tolerance and that conversely, the upregulation of SIRT1 expression led to T cell anergy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Silent information regulator 1 (SIRT1) is a type of histone deacetylase whose activity is dependent on nicotinamide adenine dinucleotide. SIRT1 plays a key role in the longevity effects elicited by calorie restriction. Recently, a neuroprotective effect of SIRT1 was reported for neurological diseases. The focus of this review is to summarize the protective effects of SIRT1 in cerebral ischemia. First, the posttranslational modifications of SIRT1 are illustrated; then, we discuss the roles of SIRT1 in cerebral immune homeostasis. Next, we introduce the deacetylase activity of SIRT1 in cerebral ischemia and provide some examples of relevant studies. In addition, we discuss several activated mediators of SIRT1, such as resveratrol, caloric restriction, ischemic preconditioning, and other proteins and compounds. Finally, we highlight a few SIRT1-related signaling pathways, such as the peroxisome proliferator-activated receptor γ coactivator 1α, nuclear transcription factor κB, uncoupling protein 2, and forkhead box O pathways. Taken together, the information compiled in this article will serve as a comprehensive reference for the actions of SIRT1 in the nervous system and will help in the design of future experimental research and promote SIRT1 as a new therapeutic target.
    Neurobiology of aging 07/2013; 34(12). DOI:10.1016/j.neurobiolaging.2013.06.008 · 4.85 Impact Factor
  • Source
    • "The acetylation of the RelA subunit of NF-kB by p300 increases its transcriptional activity (Chen et al., 2002) and this is countered by the cellular deacetylase SIRT1 (Yeung et al., 2004). SIRT1 activity is in turn blocked by HIV-1 Tat (Kwon et al., 2008). In addition, it has been demonstrated that HIV Tat and Rev transcripts are retained in the nuclei of resting CD4 + T-cells (Lassen et al., 2006) and that numerous host microRNAs can directly or indirectly downregulate HIV-1 gene expression, contributing to the maintenance of proviral latency (Chiang & Rice, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4+ memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.
    Journal of General Virology 01/2013; 94(Pt 5). DOI:10.1099/vir.0.049296-0 · 3.53 Impact Factor
  • Source
    • "Of note, SIRT1-mediated deacetylation of RelA at lysine 310 is blocked by HIV Tat. Because acetylation of lysine 310 in RelA greatly enhances transcriptional activity, this inhibitory effect of Tat could markedly boost NF-kB action and increase viral gene expression as well as expression of genes involved in inflammation and immune activation (Kwon et al. 2008). Importantly, HDAC3-mediated deacetylation of lysine 221 restores the ability of newly synthesized IkBa to bind to RelA (Sun et al. 1993), "
    Article: HIV latency
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV-1 can establish a state of latent infection at the level of individual T cells. Latently infected cells are rare in vivo and appear to arise when activated CD4(+) T cells, the major targets cells for HIV-1, become infected and survive long enough to revert back to a resting memory state, which is nonpermissive for viral gene expression. Because latent virus resides in memory T cells, it persists indefinitely even in patients on potent antiretroviral therapy. This latent reservoir is recognized as a major barrier to curing HIV-1 infection. The molecular mechanisms of latency are complex and include the absence in resting CD4(+) T cells of nuclear forms of key host transcription factors (e.g., NFκB and NFAT), the absence of Tat and associated host factors that promote efficient transcriptional elongation, epigenetic changes inhibiting HIV-1 gene expression, and transcriptional interference. The presence of a latent reservoir for HIV-1 helps explain the presence of very low levels of viremia in patients on antiretroviral therapy. These viruses are released from latently infected cells that have become activated and perhaps from other stable reservoirs but are blocked from additional rounds of replication by the drugs. Several approaches are under exploration for reactivating latent virus with the hope that this will allow elimination of the latent reservoir.
    Cold Spring Harbor Perspectives in Medicine 09/2011; 1(1):a007096. DOI:10.1101/cshperspect.a007096 · 7.56 Impact Factor
Show more

Preview

Download
3 Downloads
Available from